trending Market Intelligence /marketintelligence/en/news-insights/trending/r4-2d9rV4-nyRGt-gdgHlA2 content esgSubNav
In This List

Strongbridge Biopharma prices share offering

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector

Blog

Insight Weekly: Energy reforms after midterms; Crisis ends 'age of gas'; bank deposits fall


Strongbridge Biopharma prices share offering

Strongbridge Biopharma plc priced an underwritten public offering of 4 million shares at $6.25 apiece to raise $25 million in gross proceeds.

The offer is expected to close Oct. 6 with Cantor Fitzgerald & Co. acting as the sole book-running manager and Oppenheimer & Co. Inc. and H.C. Wainwright & Co. LLC as co-managers.

The underwriters have an option to buy up to an additional 600,000 of the shares offered.

Strongbridge plans to use the net proceeds to advance its drug pipeline, including Keveyis to treat primary periodic paralysis and Recorlev to treat Cushing's syndrome.